Swiss multinational investment bank Credit Suisse is infusing $250 million into an Israeli life sciences VC firm, bringing the fund’s total to over $400 million — a sum that surpasses even OrbiMed’s presence in Israel.
The Tel Aviv-based VC firm, called aMoon, was set up by Israeli billionaire Marius Nacht (best known for his role in global cybersecurity for founding Check Point Software Technologies) and co-founded by Yair Schindel, the former CEO of the State of Israel’s National Digital Bureau. This is aMoon’s second fund since its 2016 launch. Just last month, the firm announced it raised $200 million for the second fund, with a goal of $500 million.
The partnership between Credit Suisse and aMoon will allow the bank’s clients and institutional investors outside the United States and Canada “exclusive access” to aMoon’s portfolio of companies, a joint statement said.
The fund, aMoon II, invests in mid- to late-stage life science companies in digital health, medical technologies, and biopharmaceutical firms.
“This strategic partnership is perfectly timed to leverage the growing convergence of technology and healthcare,” said Schindel in a statement. “Breakthrough scientific research, innovative technology, and decades of digital health records make Israel an ideal launchpad for leading this global transformation in healthcare.”
Investments aren’t sequestered to Israel, though, as the firm is open to making investments in the US and Europe.
AMoon’s first fund — which totaled $200 million — invested in 16 startups, including Mapi Pharma, which announced a development and commercializing partnership in April with pharma giant Mylan for a monthly treatment for relapse remitting multiple sclerosis.
This $400 million fund at aMoon surpasses OrbiMed’s Israeli fund announced in 2016, which totaled $307 million.
Image: aMoon partners Isaac Devash, Yair Schindel, and anchor investor Marius Nacht. aMoon
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.Free Subscription